Piper Jaffray Initiates Nexvet Biopharma At Overweight

by Monica Gerson, Benzinga Staff Writer

March 2, 2015 9:49 AM | 12 seconds read | Make a Comment

Piper Jaffray initiated coverage on

Nexvet Biopharma Public Limited CompanyNVET

with a Overweight rating, according to sources. The target price for Nexvet Biopharma is set to $17. Nexvet Biopharma's shares closed at $10.03 on Friday.

Market News and Data brought to you by Benzinga APIs

Posted In: Initiation Analyst Ratings Piper Jaffray

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Piper Jaffray Initiates Nexvet Biopharma At Overweight